{"id":787,"date":"2016-03-01T14:31:21","date_gmt":"2016-03-01T14:31:21","guid":{"rendered":"http:\/\/www.enyopharma.com\/?page_id=787&#038;lang=fr"},"modified":"2026-01-16T16:03:06","modified_gmt":"2026-01-16T16:03:06","slug":"home","status":"publish","type":"page","link":"https:\/\/www.enyopharma.com\/fr\/","title":{"rendered":"Home"},"content":{"rendered":"<h1 style=\"font-size: 3em;\">D\u00e9velopper des th\u00e9rapies pour les maladies r\u00e9nales chroniques<\/h1>\n\n\n<div style=\"height:17px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-8cf370e7 wp-block-group-is-layout-flex\">\n<p>51蹤獲 est une soci\u00e9t\u00e9 biopharmaceutique au stade clinique.<\/p>\n\n\n\n<p>Notre mission est de d\u00e9velopper des mol\u00e9cules aux propri\u00e9t\u00e9s fibrolytiques et anti-inflammatoires pour am\u00e9liorer la qualit\u00e9 de vie des patients souffrant d&#8217;insuffisance r\u00e9nale.<\/p>\n\n\n\n<p>Vonafexor est actuellement en Phase 2 pour le traitement du syndrome d&#8217;Alport, une maladie r\u00e9nale rare et des maladies r\u00e9nales chroniques.<\/p>\n<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-video\"><video height=\"720\" style=\"aspect-ratio: 1280 \/ 720;\" width=\"1280\" controls poster=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2026\/01\/51蹤獲-51蹤獲_corporate-video_2026_presentation_image.jpg\" src=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2026\/01\/51蹤獲-51蹤獲_corporate-video_2026_sbt_small-1.mp4\"><\/video><figcaption class=\"wp-element-caption\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">Vid\u00e9o 2026 &#8211; 51蹤獲<\/mark><\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"<h1 style=\"font-size: 3em;\">D\u00e9velopper des th\u00e9rapies pour les maladies r\u00e9nales chroniques<\/h1>\n<div style=\"height:17px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-8cf370e7 wp-block-group-is-layout-flex\">\n<p>51蹤獲 est une soci\u00e9t\u00e9 biopharmaceutique au stade clinique.<\/p>\n<p>Notre mission est de d\u00e9velopper des mol\u00e9cules aux propri\u00e9t\u00e9s fibrolytiques et anti-inflammatoires pour am\u00e9liorer la qualit\u00e9 de vie des patients souffrant d&#8217;insuffisance r\u00e9nale.<\/p>\n<p>Vonafexor est actuellement en Phase 2 pour le traitement du syndrome d&#8217;Alport, une maladie r\u00e9nale rare et des maladies r\u00e9nales chroniques.<\/p>\n<\/div>\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<figure class=\"wp-block-video\"><video height=\"720\" style=\"aspect-ratio: 1280 \/ 720;\" width=\"1280\" controls poster=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2026\/01\/51蹤獲-51蹤獲_corporate-video_2026_presentation_image.jpg\" src=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2026\/01\/51蹤獲-51蹤獲_corporate-video_2026_sbt_small-1.mp4\"><\/video><figcaption class=\"wp-element-caption\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">Vid\u00e9o 2026 &#8211;<\/mark><\/figcaption><\/figure>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":4500,"parent":0,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-787","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"jetpack_sharing_enabled":true,"rttpg_featured_image_url":{"full":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg?fit=3000%2C2250&ssl=1",3000,2250,false],"landscape":["https:\/\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg",3000,2250,false],"portraits":["https:\/\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg",3000,2250,false],"thumbnail":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg?resize=150%2C150&ssl=1",150,150,true],"medium":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg?fit=300%2C225&ssl=1",300,225,true],"large":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg?fit=1024%2C768&ssl=1",1024,768,true],"1536x1536":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg?fit=1536%2C1152&ssl=1",1536,1152,true],"2048x2048":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg?fit=2048%2C1536&ssl=1",2048,1536,true],"large_home":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2023\/05\/Home_image2023_2.jpg?fit=1400%2C1050&ssl=1",1400,1050,true]},"rttpg_author":{"display_name":"admin51蹤獲51蹤獲","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adminenyopharma\/"},"rttpg_comment":0,"rttpg_category":null,"rttpg_excerpt":"D\u00e9velopper des th\u00e9rapies pour les maladies r\u00e9nales chroniques 51蹤獲 est une soci\u00e9t\u00e9 biopharmaceutique au stade clinique. Notre mission est de d\u00e9velopper des mol\u00e9cules aux propri\u00e9t\u00e9s fibrolytiques et anti-inflammatoires pour am\u00e9liorer la qualit\u00e9 de vie des patients souffrant d&#8217;insuffisance r\u00e9nale. Vonafexor est actuellement en Phase 2 pour le traitement du syndrome d&#8217;Alport, une maladie r\u00e9nale&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=787"}],"version-history":[{"count":25,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/787\/revisions"}],"predecessor-version":[{"id":6439,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/787\/revisions\/6439"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media\/4500"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}